200
Participants
Start Date
April 1, 2019
Primary Completion Date
August 31, 2024
Study Completion Date
September 30, 2024
rhTPO
Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
Placebo
The control group will not use any platelet-increased drugs.
RECRUITING
Shanghai General Hospital, Shanghai Jiaotong University, Shanghai
Huadong Hospital
OTHER
Shanghai Tongji Hospital, Tongji University School of Medicine
OTHER
Changhai Hospital
OTHER
Second Affiliated Hospital of Nanchang University
OTHER
Shanghai Jiao Tong University School of Medicine
OTHER
Shanghai University of Traditional Chinese Medicine
OTHER
Fudan University
OTHER
Ruilan Wang
OTHER